Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension

Journal of the American College of Cardiology

Volumn 48, Issue 7, 2006, Pages 1433-1437

  Channick, Richard N ^a   Olschewski, Horst ^b   Seeger, Werner ^c   Staub, Ted ^d   Voswinckel, Robert ^c   Rubin, Lewis J ^a  

^a UCSD MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d LungRx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; UNIPROST;

ADULT; AGED; ARTICLE; CAPILLARY HEMANGIOMA; CLINICAL ARTICLE; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; HEADACHE; HEMANGIOMATOSIS; HUMAN; LUNG ARTERY PRESSURE; LUNG CAPILLARY; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; NEBULIZER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SORE THROAT; SYNCOPE; WALKING;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 33748931278     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.05.070     Document Type: Article

References (17)

1. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard B.M., and Loyd J.E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
2. Giaid A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 (1995) 214-221
3. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
4. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
5. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
6. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
7. Simonneau G., Barst R.J., Galie N., et al., Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
8. Olschewski H., Simonneau G., Galie N., et al., Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
9. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 358 (2001) 1119-1123
10. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
11. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
12. Galie N., Ghofrani H.A., Torbicki A., et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
13. Hoeper M.M., Taha N., Bekjarova A., Gatzke R., and Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 22 (2003) 330-334
14. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
15. McLaughlin V., Oudiz R., Frost A., et al., STEP Investigators. A randomized, double-blind, placebo-controlled study of iloprost inhalation as add-on therapy to bosentan in pulmonary arterial hypertension. Chest 128 (2005) 160S
16. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
17. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349